New Takeda, Karolinska Collaboration to Identify Clinical Targets in IBD

New Takeda, Karolinska Collaboration to Identify Clinical Targets in IBD
A new collaboration to identify and validate clinical targets in inflammatory bowel disease (IBD) was recently announced by Japan’s Takeda Pharmaceutical Company, Sweden’s Karolinska Institutet, and the Structural Genomics Consortium,  a public-private charity. The collaboration involves the creation of a translational medicine research team with scientists and clinicians from Takeda, Karolinska University Hospital, and SGC. The researchers will aim to develop innovative disease models using tissue samples from a large and well-characterized IBD patient group. This will allow the testing of high-quality compounds from SGC and Takeda, which will provide information on potential cellular targets and biological pathways for the treatment of diseases such as ulcerative colitis and Crohn’s disease. "At Takeda, we take a patient centric and 'human first' research approach that focuses our thinking on unmet patient needs and prioritizes studies in human tissues to advance our understanding of the biology of gastrointestinal (GI) diseases," Gareth Hicks, PhD, head of the GI Drug Discovery Unit at Takeda, said in a press release. Hicks said the partnership with Karolinska and the SGC "is a critical element of our effort toward discovering and assessing new approaches to the treatment of IBD." The agreement states that Takeda will provide funding for the research developed over a three-year period. To maximize the impact of the col
Subscribe or to access all post and page content.